Taiwan Biotech Delegation Showcases Regional Innovation in CDMO, Cell Therapy, and Biologics at BioJapan 2026
Seventeen Taiwanese biotech companies and research institutions are showcasing capabilities in advanced CDMO, cell therapy, and biologics at BioJapan 2026. The delegation, led by the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), highlights Taiwan's life sciences sector, which generated NT$830.1 billion (US$26 billion) in revenue in 2025.
Taiwan's presence at BioJapan 2026 indicates a strategic effort to expand its biotech sector's international reach. The reported revenue of NT$830.1 billion (US$26 billion) in 2025, alongside a market value exceeding NT$1.59 trillion (US$49.8 billion) for 155 public biotech companies, suggests a sector with established financial scale. This scale, combined with capabilities like precision manufacturing and PIC/S GMP compliance, positions Taiwan as a potential partner in drug development and commercialization.
The diverse range of technologies presented, from AI-driven exosome platforms and macrophage enhancers to iPSC models and large-scale CDMO services, indicates a focus on high-growth areas within biotechnology. These offerings span early-stage drug discovery, through clinical validation, to commercial-scale manufacturing. The inclusion of organizations like the National Biotechnology Research Park also suggests an infrastructure supporting startup incubation and translational research.
The delegation's participation in BioJapan, a key regional event, underscores an intent to foster cross-border alliances rather than solely domestic growth. For companies seeking partners in Asia for drug candidate translation or scaled manufacturing, Taiwan is presenting itself as a hub that integrates advanced technical capabilities with regulatory alignment.
Share this article
Related reading
6 stories
SpaceX-Owned Cursor Considers Dropping Chinese AI Models – A Look At Some Key Details

Hoymiles showcases versatile residential solar and storage solutions at RE+ 2026

Upcoming Phones With 9,000mAh or Larger Batteries

Expect Samsung’s good-value Galaxy devices to get more expensive, report says

Probe opened over Nvidia influence on US government

